J Gynecol Oncol.  2016 May;27(3):e31. 10.3802/jgo.2016.27.e31.

Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives

  • 1Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan. smabuchi@gyne.med.osaka-u.ac.jp
  • 2Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan.


Clear cell carcinoma (CCC) of the ovary is known to show poorer sensitivity to chemotherapeutic agents and to be associated with a worse prognosis than the more common serous adenocarcinoma or endometrioid adenocarcinoma. To improve the survival of patients with ovarian CCC, the deeper understanding of the mechanism of CCC carcinogenesis as well as the efforts to develop novel treatment strategies in the setting of both front-line treatment and salvage treatment for recurrent disease are needed. In this presentation, we first summarize the mechanism responsible for carcinogenesis. Then, we highlight the promising therapeutic targets in ovarian CCC and provide information on the novel agents which inhibit these molecular targets. Moreover, we discuss on the cytotoxic anti-cancer agents that can be best combined with targeted agents in the treatment of ovarian CCC.


Adenocarcinoma, Clear Cell; Antineoplastic Agents; ARID1A; Carcinogenesis; Interleukin-6; Salvage Therapy

MeSH Terms

Adenocarcinoma, Clear Cell/drug therapy/*etiology/metabolism
Antineoplastic Agents/therapeutic use
Neoplasm Recurrence, Local/prevention & control
Ovarian Neoplasms/drug therapy/*etiology/metabolism
Antineoplastic Agents
Full Text Links
  • JGO
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr